Text Size
Trial record 3 of 774 for:    Open Studies | "Carcinoma, Bronchogenic"
Previous Study | Return to List | Next Study

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2001 by Charite University, Berlin, Germany.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
ribosepharm GmbH
Information provided by:
Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT00168922
First received: September 9, 2005
Last updated: April 27, 2006
Last verified: January 2001
History of Changes
  Purpose

Determination of response rate Assessment of toxicity and determination of "time to progression"


Condition Intervention Phase
Recurrent Small Cell Lung Cancer
 Drug: Bendamustin/Ribomustin
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Determination of response rate ( CR + PR) after cytostatic therapy with Bendamustin 120mg/m2, day 1+2, repeat d 22
  • (primary goal)

Secondary Outcome Measures:
  • Assessment of toxicity, determination of time to progression, for median survival and one-year survival rate,investigation of life quality (secondary goal)

Estimated Enrollment: 50
Study Start Date: February 2001
Estimated Study Completion Date: December 2006
Detailed Description:

Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histological proven, curative non treatable small lung cell carcinoma
  • Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases

Exclusion Criteria:

  • Brain metastases
  • WHO-PS 3 - 4
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00168922

Contacts
Contact: Ulrich Keilholz, MD +49-30-8445-3596 ulrich.keilholz@charite.de
Contact: Alexander Schmittel, MD +49-30-8445-3090 alexander.schmittel@charite.de

Locations
Germany
Hematology & Oncology Charité CBF Berlin, Germany Recruiting
Berlin, Germany, 12203
Contact: Ulrich Keilholz, MD     +49-30-8445-3596     ulrich.keilholz@charite.de    
Contact: Alexander Schmittel, MD     +49-30-8445-3090     alexander.schmittel@charite.de    
Sponsors and Collaborators
Charite University, Berlin, Germany
ribosepharm GmbH
Investigators
Principal Investigator: Ulrich Keilholz, MD Charité Campus Benjamin Franklin University Clinic
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00168922     History of Changes
Other Study ID Numbers: Haema CBF SCLC UK/AS 02
Study First Received: September 9, 2005
Last Updated: April 27, 2006
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Charite University, Berlin, Germany:
recurrent SCLC

Additional relevant MeSH terms:
Carcinoma, Bronchogenic
Lung Neoplasms
Small Cell Lung Carcinoma
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases
Bendamustine
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013